Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 7, 2014, Pages 3113-3121

  Altun, Ahmet ^a   Turgut, Nergiz Hacer ^a   Kaya, Tijen Temiz ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Colon cancer; COX 2 inhibition; DuP 697; Tyrosine kinase inhibitor

Indexed keywords

4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; PROTEIN TYROSINE KINASE; QUINOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; COLONIC NEOPLASMS; DRUG EFFECTS; HT 29 CELL LINE; HUMAN; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; HT29 CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; PROTEIN-TYROSINE KINASES; QUINOLINES; THIOPHENES;

EID: 84900839951     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.7.3113     Document Type: Article

References (60)

1. Altun A, Temiz TK, Balci E, Polat ZA, Turan M (2013). Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination. ChinJ Cancer Res, 25, 572-84.
2. Best L, Simmonds P, Baughan C, et al (2000). Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst Rev, 2, 1545.
3. Blume-Jensen P, Hunter T (2001). Oncogenic kinase signalling. Nature, 411, 355-65.
4. Bokemeyer C, Bondarenko I, Makhson A, et al (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 27, 663-71.
5. Bruheim S, Kristian A, Uenaka T, et al (2011). Antitumuor activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer, 129, 742-50.
6. Bürgermeister J, Paper DH, Vogl H, Linhardt RJ, Franz G (2002). LAPSvS1, a (1-->3) -betagalactan sulfate and its effect on angiogenesis in vitro and in vivo. Carbohydr Res, 337, 1459-66.
7. Choi S, Lim TG, Hwang MK, et al (2013). Rutin inhibits B[a] PDE-induced cyclooxygenase-2 expression by targeting EGFR kinase activity. Biochem Pharmacol, 86, 1468-75.
8. Churchman A, Baydoun AR, Hoffman R (2007). Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697). Eur J Pharmacol, 573, 176-83.
9. Coghill AE, Phipps AL, Bavry AA, et al (2012). The association between NSAID use and colorectal cancer mortality: results from women's health initiative. Cancer Epidemial Biomarkers Prev, 21, 1966-73.
10. Cohen SJ, Cohen RB, Meropol NJ (2005). Targeting signal transduction pathways in colorectal cancer more than skin deep. J Clin Oncol, 23, 5374-85.
11. Dannhardt G, Kiefer W (2001). Cyclooxygenase inhibitorscurrent status and future prospects. Eur J Med Chem, 36, 109-26.
12. Darakhshan S, Bidmeshkipour A, Khazaei M, Rabzia A, Ghanbari A (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74.
13. Demirci B, Dadandi MY, Paper DH, Franz G, Baser KH (2003). Chemical composition of the essential oil of Phlomis linearis Boiss and Bal, and biological effects on CAM assay: a safety evaluation. Z Naturforsch C, 58, 826-9.
14. Deng Y, Su Q, Mo J, et al (2013). Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells. Cancer Invest, 31, 97-102.
15. Dubbelman AC, Rosing H, Thijssenb B, et al (2012).Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J Chromatography B Analyt Technol Biomed Life Sci, 8, 25-34.
16. Ellis LM, Hicklin DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer, 8, 579-91.
17. Engelman JA, Settleman J (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev, 18, 73-9.
18. Feng LL, Liu BX, Zhong JY, Sun LB, Yu HS (2014). Effect of grape procyanidins on tumor angiogenesis in liver cancer xenograft models. Asian Pac J Cancer Prev, 15, 737-41.
19. Filardo EJ (2002). Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol, 80, 231-8.
20. Glen H, Mason S, Patel H, Macleod K, Brunton VG (2011). E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer, 11, 309.
21. Gotink KJ, Verheul HM (2010). Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action. Angiogenesis, 13, 1-14.
22. Grösch S, Maier TJ, Schiffmann S, Geisslinger G (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, 98, 736-47.
23. Heuckmann JM, Rauh D, Thomas RK (2012). Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol, 30, 3417-20.
24. Huang Wk, Chiou MJ, Yu KH, et al (2013). The association between low dose aspirin use and incidence of colorectal cancer: a nationwide cohort study. Aliment Pharmacol Ther, 38, 432-9.
25. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al (2005). Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 23, 3502-8.
26. Jiang WQ, Fu FF, Li YX, et al (2012). Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. J Zhejiang Univ Sci, 13, 663-75.
27. Koki AT, Masferrer JL (2002). Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control, 9, 28-35.
28. Ma JX, Sun YL, Wang YQ, et al (2013). Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol Res, 20, 359-68.
29. Mann M, Sheng H, Shao J, et al (2001). Targeting cyclooxygenase-2 and HER-2/neu pathway inhibits colorectal pathway inhibits colorectal carcinoma growth. Gastroenterology, 120, 1713-9.
30. Masferrer JL, Leahy KM, Koki AT, et al (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
31. Masunaga R, Kohno H, Dhar DK, et al (2000). Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res, 6, 4064-8.
32. Matsui J, Funahashi Y, Uenaka T, et al (2008). Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R)2 and VEGF-R3 kinase. Clin Cancer Res, 14, 5459-65.
33. Matsui J, Yamamoto Y, Funahashi Y, et al (2008). E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small lung cancer H146, based on angiogenesis inhibition. Int J Cancer, 122, 664-71.
34. Ogino H, Hanibuchi M, Kakiuchi S, et al (2011). E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther, 10, 1218-28.
35. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006). VEGF receptor signaling -in control of vascular function. Nat Rev Mol Cell Biol, 7, 359-71.
36. Pandurangan AK, Esa NM (2013). Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev, 14, 5543-52.
37. Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ (2008). Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol, 87, 121-9.
38. Pereg D, Lishner M (2005). Non-steroidal anti-inflammatorydrugs for the prevention and treatment of cancer. J Int Med, 258, 115-23.
39. Piazza GA, Keeton AB, Tinsley HN, et al (2009). A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res, 2, 572-80.
40. Roche Diagnostics GmbH (2008). Introduction of the RTCA SP Instrument. RTCA SP Instrument Operator's Manuel, A. Acea Biosciences, Inc. 14-16.
41. Ruder EH, Laiyemo AO, Graubard BI, et al (2011). Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol, 106, 1340-50.
42. Saltz LB (2010). Adjuvant therapy for colon cancer. Surg Oncol Clin N Am, 19, 819-27.
43. Sartore-Biachi A, Martini M, Molinari F, et al (2009). PIK3CA mutations in colorectal cancer is associated with clinical resistance to EGRF-targeted monoclonal antibodies. Cancer Res, 69, 1851-7.
44. Schönthal AH (2006). Antitumor properties of dimethylcelecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus, 20, 21.
45. Segal NH, Saltz LB (2009). Evolving treatment of advanced colon cancer. Annu Rev Med, 60, 207-19.
46. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.
47. Stocmann C, Doedans A, Weidemann A, et al (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature, 456, 814-8.
48. Tanwar L, Piplani H, Sanyal S (2010). Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor on 1,2-dimethylhydrazine dihydrochloride-inducede colon carcinogenesis. Asian Pac J Cancer Prev, 11, 1329-33.
49. Thun MJ, Henley SJ, Patrono C (2002). Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 94, 252-66.
50. Toomey DP, Murphy JF, Conlon KC (2009). Cox-2, VEGF and tumour angiogenesis. Surgeon, 7, 174-80.
51. Tortora G, Caputo R, Damiano V, et al (2003). Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res, 9, 1566-72.
52. Tuccillo C, Romano M, Troiani T, et al (2005). Antitumor activity of ZD6474, a vascular endothelial growth factor-152 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res, 11, 1268-76.
53. Turini ME, DuBois RN (2002). Cyclooxygenase-2: a therapeutic target. Annu Rev Med, 53, 35-57.
54. Van Loon K, Venook AP (2011). Adjuvant treatment of colon cancer: what is next. Curr Opin Oncol, 23, 403-9.
55. Vanneman M, DranoffG (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 12, 237-51.
56. Wang D, Dubois RN (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 29, 781-8.
57. Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE, Piazza GA (2012). A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ß-catenin transcriptional activity. Cancer Prev Res, 5, 822-33.
58. Wolpin BM, Mater RJ (2008). Systemic treatment of colorectal cancer. Gastroenterology, 134, 1296-310.
59. Xu K, Chang CM, Gao H, Shu HK(2009). Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta. Oncogene, 28, 1410-20.
60. Zhou LH, Hu Q, Sui H, Ci SJ, Wang Y, Liu NN, Yin PH, Qin JM, Li Q (2012). Tanshinone 11-a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer. Asian Pac J Cancer Prev, 13, 4453-8.